Clinical Trial

Trial Protocol ID USOR 23009_AC699-001

Trial Description

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC699 in Patients with Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer (AC699-001)

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • Jeanine L Werner, MD

Disease Types

Sponsors

  • Accutar Biotechnology, Inc.
  • Sarah Cannon Development Innovations

ClinicalTrials.gov NCT ID

  • NCT05654532